- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02446288
TMJ NextGen Pilot Study to Treat Subjects With Bruxism
May 13, 2015 updated by: Cardiox Corporation
A Pilot Study of the TMJ NextGeneration Compared to the DSG Relaxer for Reduction in Nocturnal Bruxism Episodes in Subjects Diagnosed With Sleep Bruxism
The study is an open-label, prospective, multicenter, randomized, two treatment parallel, comparison study of the TMJ NextGeneration and DSG Relaxer in the reduction of nocturnal bruxism episodes in subjects diagnosed with sleep bruxism.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The study will be conducted at multiple study centers in the U.S. Subjects will be enrolled in the trial for a period of 44 days.
The study will consist of a screening period lasting up to 30 days, a device fitting period of 14 days, and a treatment period lasting 30 days.
Subjects will visit the clinic three times during the screening period, followed by visits at Day 1, Day 14, and Day 44 of the study.
Subjects will visit the sleep center once during the screening period (Day -1) and once during the treatment period (Day 43).
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Simon Blackburn, CCRA
- Phone Number: 614.323.7034
- Email: simonblackburn@cardiox.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects at least 18 years of age;
- Subject has had a diagnosis of sleep bruxism confirmed within the past 30 days;
- Subject has an average of ≥ 1.25 bruxism episodes per hour of sleep based on two nights of screening Bruxoff™ evaluations;
- Subject is able to read and understand the ICF and has voluntarily provided written informed consent;
- Subject has a minimum of 26 remaining teeth;
- Subject has an average of ≥ 1.25 bruxism episodes per hour of sleep based on the single-night screening sleep PSG evaluations.
Exclusion Criteria:
- Subjects with any physical or behavioral disorder, which, in the opinion of the Principal Investigator, may interfere with the use of the device or compliance with the study protocol;
- Subject has a significant respiratory disease that actively requires treatment;
- Subject is taking antidepressant medication;
- Subject has a significant sleep disorder that actively requires treatment, in addition to bruxism;
- Subject is undergoing treatment for sleep apnea;
- Subjects diagnosed with rheumatoid arthritis, osteoarthritis, osteoarthrosis, or another connective tissue disorder of the head/neck region;
- Subjects who have had direct trauma to the jaw;
- Subjects who have used an occlusal appliance to treat a TMD within the previous six months;
- Subjects who have had prior TMJ or ear surgery;
- Subjects who have a narrow ear canal or impression of the ear canal, which is prolapsed due to an anatomical shift or failure of the ear canal wall structure, or a canal that does not allow for the ear canal second turn to be identified;
- Subjects with visible or congenital ear deformity as observed on targeted physical exam that does not allow for fitting of the study device;
- Subjects who have taken a narcotic pain medication in the last seven days prior to Day 1 of the study;
- Subjects who have a history of chronic ear pain unrelated to TMJ;
- Subjects who have a history of ear drainage in the past six months;
- Subjects who have active ear drainage, swelling, or redness as observed on targeted physical exam;
- Subjects whom the investigator believes may not be an appropriate candidate for an intra-oral splint due to missing or poor quality dentition or untreated pain of dental origin (pulpal pain, pericoronitis of wisdom teeth, or similar conditions).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: TMJ Next Generation
The TMJ NextGeneration device consists of a pair of small, hollow ear inserts.
These ear inserts are custom-fit to each subject's ear canals.
They are constructed from methacrylate polymers - the same material as has been used in hearing aids.
The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear.
The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear.
The proposed mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
|
|
Active Comparator: DSG Relaxer
The occlusal splint to be used in this study will be the DSG Relaxer™.
The DSG Relaxer™ is a device that has been FDA cleared for the treatment of medically diagnosed migraine pain as well as migraine associated tension-type headaches and relieving bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objective of this study is to determine the effectiveness of the TMJ NextGeneration to reduce nocturnal bruxism episodes in subjects experiencing sleep bruxism as determined by polysomnography.
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary objective of this study is to further establish the safety of the TMJ NextGeneration device as determined by adverse events.
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Simon Blackburn, CCRA, Cardiox Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Anticipated)
October 1, 2015
Study Completion (Anticipated)
November 1, 2015
Study Registration Dates
First Submitted
May 12, 2015
First Submitted That Met QC Criteria
May 13, 2015
First Posted (Estimate)
May 18, 2015
Study Record Updates
Last Update Posted (Estimate)
May 18, 2015
Last Update Submitted That Met QC Criteria
May 13, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMJ-1003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bruxism
-
Karabuk UniversityRecruiting
-
Riyadh Colleges of Dentistry and PharmacyUnknownNocturnal BruxismSaudi Arabia
-
Damascus UniversityCompletedNocturnal BruxismSyrian Arab Republic
-
University of California, San FranciscoWithdrawn
-
University of Nove de JulhoUnknown
-
Universidade Federal do Rio de JaneiroUnknown
-
CES UniversityNot yet recruitingSleep Bruxism, Childhood
-
Aydin Adnan Menderes UniversityCompleted
-
Dominik EttlinMerz PharmaceuticalsNot yet recruiting
-
Federal University of PelotasUnknown
Clinical Trials on TMJ Next Generation
-
Asan Medical CenterRecruitingPancreatic Cancer | Chemotherapy Effect | Genetic ChangeKorea, Republic of
-
Qingyuan ZhanNot yet recruiting
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingBiliary Tract Cancer (BTC)Taiwan
-
Konkuk University Medical CenterFoundation Medicine; Roche DiagnosticsRecruitingAdenocarcinoma of Lung | EGFR Activating MutationKorea, Republic of
-
Xiangya Hospital of Central South UniversityHunan Cancer Hospital; The Third Xiangya Hospital of Central South University; Hunan Provincial People's Hospital and other collaboratorsCompletedBladder Cancer | Urine | Diagnosis | BiomarkerChina
-
University Hospital HeidelbergFraunhofer Institute for Interfacial Engineering and Biotechnology; Dietmar...CompletedSepsis | Septic ShockGermany
-
Rothman Institute OrthopaedicsEnrolling by invitation
-
Huashan HospitalChildren's Hospital of Fudan University; Shanghai Jiao Tong University Affiliated...UnknownInfectious Disease | Next Generation SequencingChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingThis Study Aims to Reveal the Effectiveness, Accuracy, and Feasibility in BileChina
-
Aarhus University HospitalRecruiting